Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringles

Cancer Research

Volumn 64, Issue 19, 2004, Pages 7092-7098

  Yu, Hyun Kyung ^a   Kim, Jang Seong ^a   Lee, Ho Jeong ^a   Ahn, Jin Hyung ^a   Lee, Suk Keun ^b   Hong, Soon Won ^c   Yoon, Yeup ^a  

^a Mogam Biotechnology Research Institute   (South Korea)

^b Gangneung Wonju National University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; GENE PRODUCT; PROTEIN LK68; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; ENDOTHELIUM CELL; EX VIVO STUDY; GENE TARGETING; GENE THERAPY; GENE TRANSFER; KRINGLE DOMAIN; LIVER METASTASIS; MALE; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS; SPLEEN;

ANIMALS; APOLIPOPROTEINS; APOPROTEIN(A); APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; ENDOTHELIUM, VASCULAR; GENE THERAPY; KRINGLES; LIPOPROTEIN(A); LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC;

EID: 4944230455     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0364     Document Type: Article

References (43)

1. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990;77: 1241-6.
2. Lorenz M, Staib-Sebler E, Hochmuth K, et al. Surgical resection of liver metastases of colorectal carcinoma: short and long-term results. Semin Oncol 2000;27:112-9.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature (Lond) 2000;407:249-57.
5. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315-28.
6. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
7. Katsouras CS, Karabina SA, Tambaki AP, et al. Serum lipoprotein(a) concentrations and apolipoprotein(a) isoforms: association with the severity of clinical presentation in patients with coronary heart disease. J Cardiovasc Risk 2001;8:311-7.
8. Fless GM, Zum Mallen ME, Scanu AM. Physicochemical properties of apolipoprolein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein(a). J Biol Chem 1986;261:8712-8.
9. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature (Lond) 1987;330:132-7.
10. Guevara J Jr, Knapp RD, Honda S, Northup SR, Morrisett JD. A structural assessment of the apo[a] protein of human lipoprotein[a]. Proteins 1992;12:188-99.
11. Cao Y, Cao R, Veitonmaki N. Kringle structures and antiangiogenesis. Curr Med Chem Anti-Cane Agents 2002;2:667-81.
12. Schulter V, Koolwijk P, Peters E, et al. Impact of apolipoprotein(a) on in vitro angiogenesis. Arterioscler Thromb Vasc Biol 2001;21:433-8.
13. Trieu VN, Uckun FM. Apolipoprotein(a), a link between atherosclerosis and tumor angiogenesis. Biochem Biophys Res Commun 1999;257:714-8.
14. Kim JS, Chang JH, Yu HK, et al. Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). J Biol Chem 2003;278:29000-8.
15. Ahn JH, Kim JS, Yu HK, Lee HJ, Yoon Y. A truncated kringle domain of human apolipoprolein(a) inhibits the activation of extracellular signal-regulated kinase I and 2 through a tyrosine phosphatase-dependent pathway. J Biol Chem 2004;279: 21808-14.
16. Folkman J. The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat 1995;36:109-18.
17. Tomlinson E. Impact of the new biologies on the medical and pharmaceutical sciences. J Pharm Pharmacol 1992;44(Suppl 1):147-59.
18. Crystal RG. The body as a manufacturer of endostatin. Nat Biotechnol 1999;17: 336-7.
19. Kong HL, Crystal RG. Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst (Bethesda) 1998;90:273-86.
20. Feldman AL, Libutti SK. Progress in antiangiogenic gene therapy of cancer. Cancer (Phila) 2000;89:1181-94.
21. Dell'Eva R, Pfeffer U, Indraccolo S, Albini A, Noonan D. Inhibition of tumor angiogenesis by angiostatin: from recombinant protein to gene therapy. Endothelium 2002;9:3-10.
22. Gervaz P, Scholl B, Mainguene C, et al. Angiogenesis of liver metastases: role of sinusoidal endothelial cells. Dis Colon Rectum 2000;43:980-6.
23. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (Bethesda) 1990;82:4-6.
24. Xu R, Sun X, Tse LY, et al. Long-term expression of angiostatin suppresses metastatic liver cancer in mice. Hepatology 2003;37:1451-60.
25. Chen CT, Lin J, Li Q, et al. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Hum Gene Ther 2000;11:1983-96.
26. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
27. Solaun MS, Mendoza L, De Luca M, et al. Endostatin inhibits murine colon carcinoma sinusoidal-type metastases by preferential targeting of hepatic sinusoidal endothelium. Hepatology 2002;35:1104-16.
28. Shaheen RM, Davis DW, Liu W, et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999;59:5412-6.
29. Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 1995;6:3-18.
30. Takeda A, Stoeltzing O, Ahmad SA, et al. Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol 2002;9:610-6.
31. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.
32. Chambers AF, MacDonald IC, Schmidt EE, Morris VL, Groom AC. Clinical targets for anti-metastasis therapy. Adv Cancer Res 2000;79:91-121.
33. Luzzi KJ, MacDonald IC, Schmidt EE, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998;153:865-73.
34. Cameron MD, Schmidt EE, Kerkvliet N, et al. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res 2000;60:2541-6.
35. de Roos WK, Fallaux FJ, Marinelli AW, et al. Isolated-organ perfusion for local gene delivery: efficient adenovirus-mediated gene transfer into the liver. Gene Ther 1997; 4:55-62.
36. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-92.
37. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond) 1997;390: 404-7.
38. Drixler TA, Rinkes IH, Ritchie ED, et al. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res 2000;60:1761-5.
39. Guba M, Cernaianu G, Koehl G, et al. A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Res 2001;61:5575-9.
40. Camphausen K, Moses MA, Beecken WD, et al. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 2001;61:2207-11.
41. te Velde EA, Vogten JM, Gebbink MF, et al. Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br J Surg 2002;89:1302-9.
42. Galaup A, Opolon P, Bouquet C, et al. Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model. Mol Ther 2003;7:731-40.
43. Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (Lond) 1998;394:287-91.